Article Details

Bristol-Myers Squibb (NYSE:BMY) Rating Increased to Buy at Truist Securities

Retrieved on: 2021-04-07 15:00:00

Tags for this article:

Click the tags to see associated articles and topics

Bristol-Myers Squibb (NYSE:BMY) Rating Increased to Buy at Truist Securities. View article details on hiswai:

Excerpt

The brokerage currently has a $74.00 price objective on the biopharmaceutical company's stock, up from their prior price objective of $66.00. Truist ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up